The experiments described in this proposal are designed (1) to elucidate the mechanism of homologous DNA recombination in the orthopoxvirus vaccinia virus, and (2) to construct a novel type of recombinant vaccinia virus vector that provides """""""" runaway"""""""" expression of foreign genes. As well as increasing our understanding of the mechanism of a fundamental genetic process. these experiments will permit the design of safer and more effective vaccines based on recombinant vaccinia viruses. Vaccinia virus represents one of the very few systems in which DNA recombination in higher eukeryotic cells is accessible to both a genetic and a biochemical approach. We therefore plan to isolate recombination-deficient (rec-) mutants of the virus and to examine the structures and functions of the rec gene products using both infected cells in culture and cell-free systems. Deletion of viral rec genes that are not essential for virus replication will enhance the safety of potential vaccines that are based on vaccinia virus recombinants. In the second part of the proposal, plans are described for the construction of a vaccinia virus recombinant that expresses the gene for an RNA-dependent RNA polymerase from a nodavirus. This enzyme normally catalyzes the replication of its own mRNA and should thus be expressed at very high levels from vaccinia virus recombinants. The possibility will be explored that RNA sequences that encode proteins of general interest and importance can be rendered competent templates for replication by the nodavirus replicase by being sandwiched between sequences that function as origins of nodavirus RNA replication. It is hoped that this approach will head to the development of new high-level expression vectors and potential vaccines based on vaccinia virus recombinants.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Method to Extend Research in Time (MERIT) Award (R37)
Project #
5R37AI018270-14
Application #
2060662
Study Section
Special Emphasis Panel (NSS)
Project Start
1987-08-01
Project End
1997-05-31
Budget Start
1994-06-01
Budget End
1995-05-31
Support Year
14
Fiscal Year
1994
Total Cost
Indirect Cost
Name
University of Alabama Birmingham
Department
Microbiology/Immun/Virology
Type
Schools of Dentistry
DUNS #
004514360
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Novella, Isabel S; Ball, L Andrew; Wertz, Gail W (2004) Fitness analyses of vesicular stomatitis strains with rearranged genomes reveal replicative disadvantages. J Virol 78:9837-41
Eckerle, Lance D; Ball, L Andrew (2002) Replication of the RNA segments of a bipartite viral genome is coordinated by a transactivating subgenomic RNA. Virology 296:165-76
Wertz, Gail W; Moudy, Robin; Ball, L Andrew (2002) Adding genes to the RNA genome of vesicular stomatitis virus: positional effects on stability of expression. J Virol 76:7642-50
Flanagan, E B; Zamparo, J M; Ball, L A et al. (2001) Rearrangement of the genes of vesicular stomatitis virus eliminates clinical disease in the natural host: new strategy for vaccine development. J Virol 75:6107-14
Johnson, K N; Zeddam, J L; Ball, L A (2000) Characterization and construction of functional cDNA clones of Pariacoto virus, the first Alphanodavirus isolated outside Australasia. J Virol 74:5123-32
Flanagan, E B; Ball, L A; Wertz, G W (2000) Moving the glycoprotein gene of vesicular stomatitis virus to promoter-proximal positions accelerates and enhances the protective immune response. J Virol 74:7895-902
Ball, L A; Pringle, C R; Flanagan, B et al. (1999) Phenotypic consequences of rearranging the P, M, and G genes of vesicular stomatitis virus. J Virol 73:4705-12
Ball, L A; Johnson, K L (1999) Reverse genetics of nodaviruses. Adv Virus Res 53:229-44
Wertz, G W; Perepelitsa, V P; Ball, L A (1998) Gene rearrangement attenuates expression and lethality of a nonsegmented negative strand RNA virus. Proc Natl Acad Sci U S A 95:3501-6
Johnson, K L; Ball, L A (1997) Replication of flock house virus RNAs from primary transcripts made in cells by RNA polymerase II. J Virol 71:3323-7

Showing the most recent 10 out of 41 publications